Trump Cuts Threaten Sight-Saving Research
- Corey, a researcher, is optimistic that Harvard University's lawsuit challenging a federal funding freeze will succeed.
- Jessica Chaikof shares this hope, expressing confidence in the potential of gene therapies to treat a range of rare diseases.
- Chaikof recalls her family discovering the genetic condition.
Harvard’s lawsuit against a federal funding freeze could reshape the future of gene therapy research, impacting treatments for rare diseases.Researchers like Corey are optimistic, readying grant applications, while individuals like Jessica Chaikof, born with Usher 1F syndrome, emphasize the crucial role of consistent federal funding. This legal battle directly challenges the potential for advancing sight-saving therapies. The availability of resources is essential; the outcome will determine whether advancements in curing rare diseases move forward. News Directory 3 reported on the lawsuit outcome and its connection to the availability of funding. Discover what’s next in the fight to protect vital research.
Gene Therapy Research Hinges on Harvard Lawsuit Outcome
Updated June 24, 2025
Corey, a researcher, is optimistic that Harvard University’s lawsuit challenging a federal funding freeze will succeed. He said his grant applications will be ready for funding if the lawsuit is successful.
Jessica Chaikof shares this hope, expressing confidence in the potential of gene therapies to treat a range of rare diseases. Chaikof and her older sister, Rachel, were both born deaf, later learning that they both had Usher syndrome Type 1F after Rachel began experiencing vision problems in 2006. At the time, Chaikof was 11 years old.
Chaikof recalls her family discovering the genetic condition. “My mom didn’t want to scare me, but they knew if rachel had it, I have to have it too because it’s genetic,” she said.
Chaikof emphasizes that the future of such treatments hinges on the consistent availability of federal funding.
“And that’s the case, not just for my disease, but for any rare disease,” Chaikof says.
What’s next
The outcome of Harvard’s lawsuit could significantly impact the future of gene therapy research and the progress of treatments for rare diseases.